Sigyn Therapeutics Inc (SIGY)
5.25
0.00 (0.00%)
USD |
OTCM |
May 03, 16:00
Sigyn Therapeutics Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2020 | -0.7374 |
| December 31, 2019 | -0.772 |
| September 30, 2019 | -0.4774 |
| June 30, 2019 | -0.4818 |
| March 31, 2019 | -0.4947 |
| December 31, 2018 | -0.494 |
| September 30, 2018 | -0.671 |
| June 30, 2018 | -0.6991 |
| March 31, 2018 | -0.6809 |
| December 31, 2017 | -0.5882 |
| September 30, 2017 | -0.3963 |
| Date | Value |
|---|---|
| June 30, 2017 | -0.6822 |
| March 31, 2017 | -0.6622 |
| September 30, 2016 | -0.3573 |
| June 30, 2016 | -0.3066 |
| March 31, 2016 | -0.3757 |
| December 31, 2015 | -0.4238 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-0.772
Minimum
Dec 2019
-0.4774
Maximum
Sep 2019
-0.6172
Average
-0.6096
Median
Debt to Equity Ratio Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.00 |
| IGC Pharma Inc | 0.0152 |
| NovaBay Pharmaceuticals Inc | 0.3431 |
| Protalix BioTherapeutics Inc | 0.6033 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 0.3218M |
| Total Liabilities (Quarterly) | 3.734M |
| Shareholders Equity (Quarterly) | -3.412M |